{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:41:34Z","timestamp":1793450494209,"version":"4.5.0"},"reference-count":134,"publisher":"Annual Reviews","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:p>Cancer immunotherapies are a promising method for treating cancers and directly enhance the antitumor capabilities of a patient's immune system. In particular, therapeutic mRNA cancer vaccines are an attractive strategy as they offer a specificity and safety level that other immunotherapies are unable to achieve. Incorporation of tumor-specific or tumor-associated antigens in mRNA vaccines aims to enhance tumor antigen-specific T\u00a0cells. mRNA vaccine adjuvants often encode immune stimulating proteins such as proinflammatory cytokines, costimulatory molecules, and pattern recognition receptors or their corresponding agonists. This review summarizes prominent clinical and preclinical therapies utilizing mRNA tumor-associated or tumor-specific antigens and mRNA encoding immunostimulants delivered either as vaccine adjuvants or as monotherapies for the treatment of cancer. The limitations, challenges, and future directions of therapeutic mRNA vaccines are also discussed.<\/jats:p>","DOI":"10.1146\/annurev-bioeng-110824-034150","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:02:17Z","timestamp":1777658537000},"page":"249-272","source":"Crossref","is-referenced-by-count":4,"title":["Recent Advances in mRNA Therapeutic Cancer Vaccines"],"prefix":"10.1146","volume":"28","author":[{"given":"Amy D.","family":"Laflin","sequence":"first","affiliation":[{"name":"1Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York, USA; email: sj19@cornell.edu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Pan","sequence":"additional","affiliation":[{"name":"2Center for Cancer Prevention, Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA; email: myou@houstonmethodist.org"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"You","sequence":"additional","affiliation":[{"name":"2Center for Cancer Prevention, Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA; email: myou@houstonmethodist.org"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyi","family":"Jiang","sequence":"additional","affiliation":[{"name":"1Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York, USA; email: sj19@cornell.edu"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22","reference":[{"issue":"6","key":"B1","first-page":"375","article-title":"Cancer immunotherapy: a promising dawn in cancer research","volume":"10","year":"2020","journal-title":"Am. J. Blood Res."},{"issue":"5","key":"B2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"B3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","year":"2021","journal-title":"Mol. Cancer"},{"issue":"11","key":"B4","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1172\/JCI134915","article-title":"mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"7830","key":"B5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","year":"2020","journal-title":"Nature"},{"issue":"20","key":"B6","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2\u2014preliminary report","volume":"383","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7876","key":"B7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","article-title":"The tangled history of mRNA vaccines","volume":"597","year":"2021","journal-title":"Nature"},{"issue":"10","key":"B8","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials of mRNA vaccines for cancer treatment","volume":"23","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"B9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1084\/jem.184.2.465","article-title":"Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo","volume":"184","year":"1996","journal-title":"J. Exp. Med."},{"issue":"20","key":"B10","doi-asserted-by":"crossref","first-page":"8304","DOI":"10.1021\/acs.nanolett.2c03234","article-title":"Phosphatidylserine lipid nanoparticles promote systemic RNA delivery to secondary lymphoid organs","volume":"22","year":"2022","journal-title":"Nano Lett"},{"issue":"8056","key":"B11","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","year":"2025","journal-title":"Nature"},{"issue":"11","key":"B12","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/mt.2016.161","article-title":"Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses","volume":"24","year":"2016","journal-title":"Mol. Ther."},{"key":"B13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jconrel.2024.10.035","article-title":"Recent advances in mRNA-based cancer vaccines encoding immunostimulants and their delivery strategies","volume":"376","year":"2024","journal-title":"J. Control. Release"},{"issue":"10","key":"B14","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1007\/s12274-018-2091-z","article-title":"Recent advances in mRNA vaccine delivery","volume":"11","year":"2018","journal-title":"Nano Res"},{"issue":"7","key":"B15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"B16","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/1097-0142(19850315)55:6<1236::AID-CNCR2820550616>3.0.CO;2-#","article-title":"Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer","volume":"55","year":"1985","journal-title":"Cancer"},{"issue":"3","key":"B17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1053\/j.seminoncol.2012.02.007","article-title":"Whole cell vaccines\u2014past progress and future strategies","volume":"39","year":"2012","journal-title":"Semin. Oncol."},{"issue":"4","key":"B18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors","volume":"38","year":"2020","journal-title":"Cancer Cell"},{"issue":"6475","key":"B19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/369067a0","article-title":"CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma","volume":"369","year":"1994","journal-title":"Nature"},{"issue":"7662","key":"B20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","year":"2017","journal-title":"Nature"},{"issue":"1","key":"B21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41698-023-00461-1","article-title":"Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention","volume":"7","year":"2023","journal-title":"NPJ Precis. Onc."},{"issue":"7662","key":"B22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","year":"2017","journal-title":"Nature"},{"issue":"47","key":"B23","doi-asserted-by":"crossref","first-page":"82689","DOI":"10.18632\/oncotarget.19831","article-title":"Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine","volume":"8","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"B24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1158\/1940-6207.CAPR-13-0182","article-title":"A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease","volume":"6","year":"2013","journal-title":"Cancer Prev. Res."},{"issue":"1","key":"B25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41541-020-00273-5","article-title":"A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope","volume":"6","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"12","key":"B26","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1084\/jem.188.12.2357","article-title":"The central role of CD4+ T cells in the antitumor immune response","volume":"188","year":"1998","journal-title":"J. Exp. Med."},{"issue":"5","key":"B27","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1084\/jem.187.5.693","article-title":"Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors","volume":"187","year":"1998","journal-title":"J. Exp. Med."},{"issue":"1","key":"B28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/1078-0432.CCR-07-1880","article-title":"Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine","volume":"14","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B29","article-title":"How to predict binding specificity and ligands for new MHC-II alleles with MixMHC2pred","volume-title":"HLA Typing: Methods and Protocols","volume":"2809","year":"2024"},{"issue":"2","key":"B30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","year":"2020","journal-title":"Cell"},{"issue":"9","key":"B31","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","article-title":"Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer","volume":"40","year":"2022","journal-title":"Cancer Cell"},{"issue":"11","key":"B32","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1172\/JCI134915","article-title":"mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"16 Suppl.","key":"B33","first-page":"6539","article-title":"Bioinformatics algorithm of mRNA-4157 identifies neoantigens with pre-existing TIL reactivities in colorectal tumors","volume":"80","year":"2020","journal-title":"Cancer Res"},{"issue":"15 Suppl.","key":"B34","first-page":"2523","article-title":"A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors","volume":"37","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"B35","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","article-title":"T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study","volume":"14","year":"2024","journal-title":"Cancer Discov"},{"issue":"10427","key":"B36","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","year":"2024","journal-title":"Lancet"},{"issue":"7963","key":"B37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","year":"2023","journal-title":"Nature"},{"issue":"7738","key":"B38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","year":"2019","journal-title":"Nature"},{"issue":"8056","key":"B39","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","year":"2025","journal-title":"Nature"},{"issue":"5","key":"B40","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s43018-021-00210-y","article-title":"Targeting public neoantigens for cancer immunotherapy","volume":"2","year":"2021","journal-title":"Nat. Cancer"},{"key":"B41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-cancerbio-061521-082114","article-title":"Targeting driver oncogenes and other public neoantigens using T\u00a0cell receptor-based cellular therapy","volume":"7","year":"2023","journal-title":"Annu. Rev. Cancer Biol."},{"key":"B42","doi-asserted-by":"crossref","first-page":"1324744","DOI":"10.3389\/fimmu.2023.1324744","article-title":"Oncolytic vaccinia virus and cancer immunotherapy","volume":"14","year":"2024","journal-title":"Front. Immunol."},{"issue":"2","key":"B43","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","year":"2023","journal-title":"Trends Cancer"},{"issue":"4","key":"B44","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ccell.2018.03.011","article-title":"Oncolytic viruses as antigen-agnostic cancer vaccines","volume":"33","year":"2018","journal-title":"Cancer Cell"},{"key":"B45","doi-asserted-by":"crossref","first-page":"762796","DOI":"10.3389\/fcell.2021.762796","article-title":"Clinical and immunological effects of p53-targeting vaccines","volume":"9","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"B46","doi-asserted-by":"crossref","first-page":"101324","DOI":"10.1016\/j.mam.2024.101324","article-title":"Cancer vaccines: target antigens, vaccine platforms and preclinical models","volume":"101","year":"2025","journal-title":"Mol. Aspects Med."},{"issue":"6","key":"B47","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cllc.2014.06.002","article-title":"Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation","volume":"15","year":"2014","journal-title":"Clin. Lung Cancer"},{"issue":"2","key":"B48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00002371-199903000-00007","article-title":"A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors","volume":"22","year":"1999","journal-title":"J. Immunother."},{"issue":"2","key":"B49","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","year":"2024","journal-title":"Nat. Med."},{"key":"B50","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ebiom.2019.10.044","article-title":"Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator","volume":"49","year":"2019","journal-title":"eBioMedicine"},{"issue":"31","key":"B51","doi-asserted-by":"crossref","first-page":"e00181","DOI":"10.1002\/advs.202500181","article-title":"An engineered soluble single-chain TCR engager for KRAS-G12V specific tumor immunotherapy","volume":"12","year":"2025","journal-title":"Adv. Sci."},{"issue":"4","key":"B52","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","article-title":"A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results","volume":"30","year":"2024","journal-title":"Nat. Med."},{"issue":"11","key":"B53","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1007\/s00432-023-04805-z","article-title":"mRNA vaccination in breast cancer: current progress and future direction","volume":"149","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"2","key":"B54","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10549-010-0844-9","article-title":"High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer","volume":"125","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"17","key":"B55","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research","volume":"15","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"5038","key":"B56","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","year":"1991","journal-title":"Science"},{"key":"B57","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2018.04.009","article-title":"MAGE-A antigens as targets for cancer immunotherapy","volume":"67","year":"2018","journal-title":"Cancer Treatment Rev"},{"key":"B58","doi-asserted-by":"crossref","first-page":"1255799","DOI":"10.3389\/fimmu.2023.1255799","article-title":"Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment","volume":"14","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"B59","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1158\/1078-0432.CCR-16-2057","article-title":"Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination","volume":"23","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"B60","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3390\/cancers15061779","article-title":"The melanoma-associated antigen family A (MAGE-A): a promising target for cancer immunotherapy?","volume":"15","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"B61","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10549-020-05638-x","article-title":"Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence","volume":"181","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"B62","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1158\/1078-0432.CCR-07-1448","article-title":"Combined clinical trial results of a HER2\/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute clinical trials group study I-01 and I-02","volume":"14","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"B63","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1158\/1078-0432.CCR-18-2867","article-title":"Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial","volume":"25","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"52","key":"B64","doi-asserted-by":"crossref","first-page":"e36793","DOI":"10.1097\/MD.0000000000036793","article-title":"AE37 HER2-targeted vaccine in the prevention of breast cancer recurrence: a mini narrative review of current evidence","volume":"102","year":"2023","journal-title":"Medicine"},{"issue":"1","key":"B65","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/13543784.2021.1849140","article-title":"AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence","volume":"30","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"9","key":"B66","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/sj.cgt.7700842","article-title":"Cotransfection of dendritic cells with RNA coding for HER-2\/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes","volume":"12","year":"2005","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"B67","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1158\/1078-0432.CCR-18-3102","article-title":"Vaccine-induced memory CD8+ T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study","volume":"25","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"B68","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41417-023-00587-1","article-title":"Clinical trials of self-replicating RNA-based cancer vaccines","volume":"30","year":"2023","journal-title":"Cancer Gene Ther"},{"issue":"15","key":"B69","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.4161\/cbt.8.15.9133","article-title":"Enhancing immune responses to tumor-associated antigens","volume":"8","year":"2009","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"B70","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41541-023-00760-5","article-title":"The advances of adjuvants in mRNA vaccines","volume":"8","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"1","key":"B71","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12951-024-02590-6","article-title":"Adjuvants for cancer mRNA vaccines in the era of nanotechnology: strategies, applications, and future directions","volume":"22","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"B72","year":"2025"},{"key":"B73","year":"2025"},{"issue":"2","key":"B74","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cdd.2014.134","article-title":"New insights into IL-12-mediated tumor suppression","volume":"22","year":"2015","journal-title":"Cell Death Differ"},{"issue":"1","key":"B75","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-017-01385-8","article-title":"Re-designing interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent","volume":"8","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"B76","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s40425-018-0431-x","article-title":"Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma","volume":"6","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"8 Suppl.","key":"B77","first-page":"CT004 (Abstr.","article-title":"Intratumoral (IT) MEDI1191 + durvalumab (D): update on the first-in-human study in advanced solid tumors","volume":"83","year":"2023","journal-title":"Cancer Res"},{"issue":"16 Suppl.","key":"B78","first-page":"2539","article-title":"A phase I study to evaluate the safety and tolerability of JCXH-211 (a self-replicating mRNA encoding IL-12) intratumoral injection in patients with malignant solid tumors: results from the phase Ia dose escalation","volume":"42","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B79","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2022.03.021","article-title":"Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy","volume":"345","year":"2022","journal-title":"J. Control. Release"},{"issue":"2","key":"B80","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/imt.14.95","article-title":"The yin and yang aspects of IL-27 in induction of cancer-specific T-cell responses and immunotherapy","volume":"7","year":"2015","journal-title":"Immunotherapy"},{"issue":"6","key":"B81","doi-asserted-by":"crossref","first-page":"e1163462","DOI":"10.1080\/2162402X.2016.1163462","article-title":"Role of IL-2 in cancer immunotherapy","volume":"5","year":"2016","journal-title":"OncoImmunology"},{"key":"B82","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jconrel.2024.03.016","article-title":"Tumor-activated IL-2 mRNA delivered by lipid nanoparticles for cancer immunotherapy","volume":"368","year":"2024","journal-title":"J. Control. Release"},{"issue":"4","key":"B83","doi-asserted-by":"crossref","first-page":"458B","DOI":"10.1378\/chest.132.4_MeetingAbstracts.458b","article-title":"IL-7 enhances the anti-tumor response in non-small cell lung cancer","volume":"132","year":"2007","journal-title":"Chest"},{"issue":"3","key":"B84","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1158\/2326-6066.CIR-15-0009","article-title":"The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy","volume":"3","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"9","key":"B85","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1021\/acs.molpharmaceut.0c00451","article-title":"Efficient colorectal cancer gene therapy with IL-15 mRNA nanoformulation","volume":"17","year":"2020","journal-title":"Mol. Pharm."},{"issue":"610","key":"B86","doi-asserted-by":"crossref","first-page":"eabc7804","DOI":"10.1126\/scitranslmed.abc7804","article-title":"Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models","volume":"13","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"B87","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/1078-0432.CCR-24-1983","article-title":"A phase I, first-in-human, dose-escalation, expansion trial of cytokine-encoding synthetic mRNA mixture alone or with cemiplimab in advanced solid tumors","volume":"31","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"B88","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtn.2022.09.010","article-title":"Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy","volume":"30","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"108","key":"B89","doi-asserted-by":"crossref","first-page":"eads1328","DOI":"10.1126\/sciimmunol.ads1328","article-title":"An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses","volume":"10","year":"2025","journal-title":"Sci. Immunol."},{"issue":"9","key":"B90","doi-asserted-by":"crossref","first-page":"e20241454","DOI":"10.1084\/jem.20241454","article-title":"Membrane-IL12 adjuvant mRNA vaccine polarizes pre-effector T cells for optimized tumor control","volume":"222","year":"2025","journal-title":"J. Exp. Med."},{"issue":"10","key":"B91","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1158\/2326-6066.CIR-23-0701","article-title":"RNA-encoded interleukin 2 with extended bioavailability amplifies RNA vaccine-induced antitumor T-cell immunity","volume":"12","year":"2024","journal-title":"Cancer Immunol. Res."},{"issue":"11","key":"B92","doi-asserted-by":"crossref","first-page":"e1232237","DOI":"10.1080\/2162402X.2016.1232237","article-title":"Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells","volume":"5","year":"2016","journal-title":"OncoImmunology"},{"issue":"2","key":"B93","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1349-7006.2007.00698.x","article-title":"Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected with tumor RNA and granulocyte macrophage colony-stimulating factor RNA","volume":"99","year":"2008","journal-title":"Cancer Sci"},{"issue":"9","key":"B94","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","year":"2022","journal-title":"Biomolecules"},{"issue":"24","key":"B95","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1158\/0008-5472.CAN-12-4174","article-title":"OX40 is a potent immune-stimulating target in late-stage cancer patients","volume":"73","year":"2013","journal-title":"Cancer Res"},{"key":"B96","doi-asserted-by":"crossref","first-page":"975408","DOI":"10.3389\/fonc.2022.975408","article-title":"An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma","volume":"12","year":"2022","journal-title":"Front. Oncol."},{"issue":"16 Suppl.","key":"B97","first-page":"CT032 (Abstr.","article-title":"A phase 1\/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies","volume":"80","year":"2020","journal-title":"Cancer Res"},{"issue":"6","key":"B98","doi-asserted-by":"crossref","first-page":"oyaf115","DOI":"10.1093\/oncolo\/oyaf115","article-title":"First-in-human phase I\/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer","volume":"30","year":"2025","journal-title":"Oncologist"},{"key":"B99","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.2147\/IJN.S479434","article-title":"Enhanced antitumor immunity through T cell activation with optimized tandem double-OX40L mRNAs","volume":"20","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"B100","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1038\/s41467-021-27434-x","article-title":"Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy","volume":"12","year":"2021","journal-title":"Nat. Commun."},{"issue":"11","key":"B101","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41565-023-01453-9","article-title":"Close the cancer\u2013immunity cycle by integrating lipid nanoparticle\u2013mRNA formulations and dendritic cell therapy","volume":"18","year":"2023","journal-title":"Nat. Nanotechnol."},{"issue":"7","key":"B102","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/0008-5472.CAN-18-2867","article-title":"Local delivery of Ox40l, Cd80, and Cd86 mRNA kindles global anticancer immunity","volume":"79","year":"2019","journal-title":"Cancer Res"},{"issue":"4","key":"B103","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.berh.2009.12.015","article-title":"Co-stimulation and T cells as therapeutic targets","volume":"24","year":"2010","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"5","key":"B104","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/08923973.2018.1510959","article-title":"Enhanced CD40 and ICOSL expression on dendritic cells surface improve anti-tumor immune responses; effectiveness of mRNA\/chitosan nanoparticles","volume":"40","year":"2018","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"12","key":"B105","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1080\/21645515.2021.1964316","article-title":"Using PAMPs and DAMPs as adjuvants in cancer vaccines","volume":"17","year":"2021","journal-title":"Hum. Vaccines Immunotherapeut."},{"issue":"45","key":"B106","doi-asserted-by":"crossref","first-page":"21782","DOI":"10.1039\/C9NR05475H","article-title":"Hybrid nanovaccine for the co-delivery of the mRNA antigen and adjuvant","volume":"11","year":"2019","journal-title":"Nanoscale"},{"key":"B107","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2023.03.041","article-title":"Spleen-selective co-delivery of mRNA and TLR4 agonist-loaded LNPs for synergistic immunostimulation and Th1 immune responses","volume":"357","year":"2023","journal-title":"J. Control. Release"},{"key":"B108","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jconrel.2017.09.041","article-title":"Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA","volume":"266","year":"2017","journal-title":"J. Control. Release"},{"key":"B109","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.actbio.2023.07.059","article-title":"Immunotherapeutic treatment of lung cancer and bone metastasis with a mPLA\/mRNA tumor vaccine","volume":"169","year":"2023","journal-title":"Acta Biomater"},{"issue":"1","key":"B110","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41392-023-01479-4","article-title":"Incorporation of a Toll-like receptor 2\/6 agonist potentiates mRNA vaccines against cancer and infectious diseases","volume":"8","year":"2023","journal-title":"Sig. Transduct. Target Ther."},{"issue":"4","key":"B111","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1039\/C9BM01564G","article-title":"Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy","volume":"8","year":"2020","journal-title":"Biomater. Sci."},{"key":"B112","doi-asserted-by":"crossref","first-page":"120431","DOI":"10.1016\/j.biomaterials.2020.120431","article-title":"Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice","volume":"266","year":"2021","journal-title":"Biomaterials"},{"issue":"34","key":"B113","doi-asserted-by":"crossref","first-page":"e04886","DOI":"10.1002\/advs.202504886","article-title":"KRAS mRNA spleen-targeting lipid nanoparticles synergize with irinotecan silicasomes to robustly augment the cancer immunity cycle in pancreatic cancer","volume":"12","year":"2025","journal-title":"Adv. Sci."},{"issue":"3","key":"B114","doi-asserted-by":"crossref","first-page":"102623","DOI":"10.1016\/j.omtn.2025.102623","article-title":"Lipid nanoparticle codelivery of an oligonucleotide-based cGAS-agonistic adjuvant and peptide or mRNA vaccines for cancer combination immunotherapy","volume":"36","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"10","key":"B115","doi-asserted-by":"crossref","first-page":"nwad214","DOI":"10.1093\/nsr\/nwad214","article-title":"STING agonist-boosted mRNA immunization via intelligent design of nanovaccines for enhancing cancer immunotherapy","volume":"10","year":"2023","journal-title":"Natl. Sci. Rev."},{"key":"B116","doi-asserted-by":"crossref","first-page":"1454504","DOI":"10.3389\/fimmu.2024.1454504","article-title":"Intratumoral delivery of mRNA encoding the endogenous TLR2\/6 agonist UNE-C1 induces immunogenic cell death and enhances antitumor activity","volume":"15","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"B117","doi-asserted-by":"crossref","first-page":"183","DOI":"10.24272\/j.issn.2095-8137.2022.464","article-title":"Current understanding of the cGAS-STING signaling pathway: structure, regulatory mechanisms, and related diseases","volume":"44","year":"2023","journal-title":"Zool. Res."},{"issue":"7","key":"B118","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.ymthe.2021.03.002","article-title":"2021. mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ T cell response","volume":"29","journal-title":"Mol. Ther."},{"issue":"5","key":"B119","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/2326-6066.CIR-24-0804","article-title":"cGAS mRNA-based immune agonist promotes vaccine responses and antitumor immunity","volume":"13","year":"2025","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"B120","doi-asserted-by":"crossref","first-page":"e0250623","DOI":"10.1128\/mbio.02506-23","article-title":"mRNAs encoding self-DNA reactive cGAS enhance the immunogenicity of lipid nanoparticle vaccines","volume":"14","year":"2023","journal-title":"mBio"},{"issue":"8 Suppl. 1","key":"B121","first-page":"3552","article-title":"An mRNA-encoded adjuvant-enzyme activates STING to enhance the immunogenicity of vaccines targeting human papillomavirus positive cancers","volume":"85","year":"2025","journal-title":"Cancer Res"},{"key":"B122","doi-asserted-by":"crossref","first-page":"122185","DOI":"10.1016\/j.biomaterials.2023.122185","article-title":"Polymeric nanoparticle gel for intracellular mRNA delivery and immunological reprogramming of tumors","volume":"300","year":"2023","journal-title":"Biomaterials"},{"issue":"477","key":"B123","doi-asserted-by":"crossref","first-page":"eaat9143","DOI":"10.1126\/scitranslmed.aat9143","article-title":"Durable anticancer immunity from intratumoral administration of IL-23, IL-36\u03b3, and OX40L mRNAs","volume":"11","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"B124","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamaoncol.2024.5927","article-title":"Intratumoral injection of mRNA-2752 and pembrolizumab for high-risk ductal carcinoma in situ: a phase 1 nonrandomized clinical trial","volume":"11","year":"2025","journal-title":"JAMA Oncol"},{"issue":"15 Suppl.","key":"B125","first-page":"3092","article-title":"A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36\u03b3, for intratumoral (iTu) injection alone and in combination with durvalumab","volume":"38","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"B126","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/mt.2008.77","article-title":"Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA","volume":"16","year":"2008","journal-title":"Mol. Ther."},{"issue":"2","key":"B127","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2326-6066.CIR-15-0163","article-title":"Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells","volume":"4","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"B128","doi-asserted-by":"crossref","first-page":"2373526","DOI":"10.1080\/2162402X.2024.2373526","article-title":"Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity","volume":"13","year":"2024","journal-title":"OncoImmunology"},{"issue":"7","key":"B129","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1158\/0008-5472.CAN-11-2957","article-title":"Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy","volume":"72","year":"2012","journal-title":"Cancer Res"},{"issue":"8","key":"B130","doi-asserted-by":"crossref","first-page":"e1019197","DOI":"10.1080\/2162402X.2015.1019197","article-title":"Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients","volume":"4","year":"2015","journal-title":"OncoImmunology"},{"issue":"10","key":"B131","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1093\/annonc\/mdt245","article-title":"A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients","volume":"24","year":"2013","journal-title":"Ann. Oncol."},{"issue":"1","key":"B132","doi-asserted-by":"crossref","first-page":"e000329","DOI":"10.1136\/jitc-2019-000329","article-title":"TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma","volume":"8","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"15 Suppl.","key":"B133","first-page":"3014","article-title":"Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with ipilimumab in patients with pretreated advanced melanoma","volume":"32","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"15 Suppl.","key":"B134","first-page":"2641","article-title":"A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: analysis of safety and immunogenicity","volume":"37","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Annual Review of Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.annualreviews.org\/content\/journals\/10.1146\/annurev-bioeng-110824-034150?crawler=true&mimetype=application\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:44:23Z","timestamp":1777697063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.annualreviews.org\/content\/journals\/10.1146\/annurev-bioeng-110824-034150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":134,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1146\/annurev-bioeng-110824-034150","relation":{},"ISSN":["1523-9829","1545-4274"],"issn-type":[{"value":"1523-9829","type":"print"},{"value":"1545-4274","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}